Our studies suggest that IL-2cx/ICs+ICIs treatment leads to limited stimulation of tumor-specific CD8+ T cells since T cells in the tumor microenvironment express PD-1 and are exhausted, with little or no CD25 expression. The gene discussed is CD8A; the disease is neoplasm.